边缘区淋巴瘤的大剂量治疗与自体干细胞移植:EBMT淋巴瘤工作组与FIL-GITMO的回顾性研究
该回顾性研究纳入1994至2013年间接受首次自体干细胞移植的199例边缘区淋巴瘤患者(111例MALT淋巴瘤、55例结淋巴结边缘区淋巴瘤、33例脾边缘区淋巴瘤),中位随访5年,5年无事件生存率53%、总生存率73%,复发/进展累积发生率38%、非复发死亡率9%、第二肿瘤累积发生率6%。多因素分析显示年龄≥65岁与较短的无事件生存和总生存相关,脾边缘区淋巴瘤患者总生存短于MALT淋巴瘤患者。作者认为自体干细胞移植可能对多线化免疫治疗失败的边缘区淋巴瘤患者提供临床获益。
要点
- 199例边缘区淋巴瘤患者接受首次自体干细胞移植,中位年龄56岁,中位既往治疗线数为2。
- 5年无事件生存率53%、总生存率73%,复发/进展累积发生率38%、非复发死亡率9%。
- 年龄≥65岁与较短的无事件生存和总生存相关;脾边缘区淋巴瘤总生存短于MALT淋巴瘤。
核心结论
- 自体干细胞移植可能对多线化免疫治疗失败的边缘区淋巴瘤患者提供临床获益。
研究设计与样本
- 回顾性研究,纳入1994至2013年间接受首次自体干细胞移植的199例非转化结内、结外(MALT)或脾边缘区淋巴瘤患者,年龄≥18岁,数据报告至欧洲血液与骨髓移植学会、意大利淋巴瘤基金会或意大利骨髓移植登记组。
主要发现
- 中位随访5年,5年复发/进展累积发生率为38%,非复发死亡率为9%。
- 5年无事件生存率为53%,总生存率为73%。
- 5年第二肿瘤累积发生率为6%。
- 多因素分析显示年龄≥65岁与较短的无事件生存和总生存相关。
- 脾边缘区淋巴瘤患者的总生存短于MALT淋巴瘤患者。
关键数值与推荐
- 中位移植年龄为56岁。
- 中位既往治疗线数为2(范围1-8),其中71%曾接受利妥昔单抗治疗。
- 95%的患者为化疗敏感性疾病,89%接受了基于化疗的大剂量方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non-transformed nodal, extra-nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy-based high-dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub-group and more transplants performed in recent years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative incidence of relapse/progression and non-relapse mortality were 38% and 9%, respectively. Five-year event-free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five-year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.
引用
- Avivi I, Arcaini L, Ferretti VV, et al. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. Br J Haematol. 2018. PMID: 29984825. doi:10.1111/bjh.15454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。